An expanded access record providing Upadacitinib in Crohn Disease, Ulcerative Colitis and Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), sponsored by AbbVie. Available. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by AbbVie · Expanded access
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Exclusion Criteria:
Upadacitinib will be administered as oral solution.
Also known as: ABT-494, Rinvoq, C25-267
No study locations are listed for this record.
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
Contact the providerGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AbbVie